• Publications
  • Influence
A Multicenter Study of Recombinant Factor VI 11 ( Recombinate ) : Safety , Efficacy , and Inhibitor Risk in Previously Untreated Patients With Hemophilia A
In July 1990, the Recombinate Study Group initiated a prospective, open-labeled investigation of recombinant factor Vlll (r-FVIII) to assess its safety and efficacy and to characterize the naturalExpand
  • 139
  • 1